A Retrospective Analysis of Clinical Features and Treatment of the Inflammatory Bowel Disease in China
CONCLUSION: The findings of the current study may provide evidence-based information for Chinese gastroenterologists to treat IBD more effectively in the future.PMID:35757458 | PMC:PMC9231537 | DOI:10.2147/JIR.S353329 (Source: Cell Research)
Source: Cell Research - June 27, 2022 Category: Cytology Authors: Su'e Shao Meifang Huang Heng Zhang Gangqiang Peng Min Song Jing Liu Dan Xu Source Type: research

EE142 Cost-Effectiveness Analysis of Biosimilars Based Treatment Sequences for Moderate-to-Severe Crohn Disease in Spain
Crohn's disease (CD) yields a considerable burden to the Spanish National Health System (NHS). Thanks to the advent of adalimumab and infliximab biosimilars (bADA, bINF), costs burden decreased substantially. However, a further assessment on additional efficiencies is warranted. The NHS ’s Willingness to Pay (WTP) per additional Quality Adjusted Life Year (QALY) could be considered an important metric to assess. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: JM Fernandez Santos, E Monte Boquet, J Borr ás Blasco, E Romero de la Cruz, R González Galán, MK Singh, V Sharma, V Merino-Bohórquez Source Type: research

CO41 Health Outcomes and Resource Utilization in a Real-World Cohort of Hospitalized Crohn's Disease Patients
To characterize resource utilization and health outcomes for hospitalized Crohn ’s disease (CD) patients. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: E Aliyev, S Seabury, M Vu Source Type: research

RWD45 Real-World Utilization of Top-Down and Step-up Therapy and Initial Costs in Crohn ’s Disease
Medication treatment strategies for Crohn ’s disease (CD) include step-up (SU) therapy, which initiates with oral anti-inflammatory agents, and top-down (TD) therapy, which initiates with biologics or immunomodulators. The real-world utilization and short-term medical costs associated with these treatment strategies are not well described . This research examined the prevalence of TD therapy use over time and first-year direct medical expenditures among patients initiating CD medication treatment with SU as compared with TD therapy in a real-world setting. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: K Shah, AR Caffrey, A Szczotka, D Belazi, SJ Kogut Source Type: research

PCR117 Adherence to Biologics, Hospitalizations, and Medical Costs in Patients with Ulcerative Colitis and Crohn's Disease Using the Marketscan Commercial Claims and Encounters Database
The goal of this study was to evaluate the association between adherence to biologic medications, medical costs, hospitalizations, and bed days in patients with ulcerative colitis (UC) or Crohn ’s disease. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: E Witt, H Kirkham, R Baiano Source Type: research

EPH46 Change in Persistence between Biologic and Biosimilar of Infliximab in the US
Infliximab is a biologic drug administered in medical setting and has biosimilars like Infliximab-dyyb and Infliximab-abda are used in the US for the treatment of multiple diseases like rheumatoid arthritis, plaque psoriasis, ulcerative colitis, and crohn ’s disease. Our study aim is to identify and observe the change in persistence of infliximab and its two biosimilars for above mentioned diseases. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: S Bhalani, N Mishra, A Gaur, I Kukreja, A Roy, A Chopra, A Gupta, L Brooks, M Sulzicki, V Verma, S Pandey, S Field, B Krebs Source Type: research

EE484 Evaluation of Health Care Resource Utilization and Costs Among Bio-Experienced Crohn's Disease Patients Treated with Biologics with Two Years of Follow-up
This study examined Crohn ’s Disease (CD)-related health care resource utilization (HCRU) and costs among bio-experienced CD patients treated with biologics over a 2-year follow-up. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: A Cyhaniuk, R Zhao, Z Ding, P Gupta, S Kachroo Source Type: research

EE374 Budget Impact of Adalimumab Sandoz (BIOSIMILAR) in Comparison to Adalimumab- Reference Product in the Management of Autoimmune Diseases in Dubai
Autoimmune disorders (AD) such as Rheumatoid Arthritis, Ankylosing Spondyloarthropathy, Ulcerative Colitis, Crohn ’s disease, Psoriatic Arthritis, Uveitis and Hidradenitis suppurativa have partially overlapping clinical manifestations of inflammation. Adalimumab Sandoz (biosimilar) is commonly used for management of several ADs. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: M Farghaly, MA Sara Ahmad, Y Sharma, SS Sultana, O Mohammed Source Type: research

EE301 Improvement in Work Productivity Loss and Associated Costs for Crohn's Disease Patients Receiving Ustekinumab in the United States: Findings from a Real-World Survey
Work-productivity loss (WPL) is an important contributor to the economic burden of Crohn ’s disease (CD). Ustekinumab (UST) is a biologic for treating adults with moderate-to-severe CD. We aimed to report WPL and associated costs in patients with CD receiving UST, relative to those with moderate-to-severe CD not receiving UST, in the real world. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: Z Ding, E Muser, J Izanec, A Roughley, R Lukanova, J Kershaw Source Type: research

EE281 Evaluation of Health Care Resource Utilization and Costs Among Bio Na ïve Crohn’s Disease Patients Initiating Biologics with Two Years of Follow-up
This study examined Crohn ’s Disease (CD)-related health care resource utilization (HCRU) and costs among bio-naïve CD patients initiating biologics over a 2-year follow-up period. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: A Cyhaniuk, R Zhao, Z Ding, P Gupta, S Kachroo Source Type: research

EE215 Higher Work Impairment and Increased Healthcare Resource Utilization in Patients with Crohn's Perianal Fistula: Results from a Global Burden of Illness Study
This study assessed the impact of PF on work productivity and healthcare resource utilization (HCRU) in patients with CD with and without PF. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: C Karki, P Geransar, G Hantsbarger, K Lee, M Perovic, L Raven, M Sajak-Szczerba, E Sharpe, A Silber, P Tozer Source Type: research

Clinical value of the expression levels of protein tyrosine phosphatase non-receptor type 22.6 mRNA in peripheral blood mononuclear cells in Crohn's disease
CONCLUSIONS: The expression levels of PTPN22.6 mRNA can be used as an indicator to help predict CD diagnosis, disease activity, serum CRP level and behavior type of CD disease.PMID:35751647 | DOI:10.1093/cei/uxac061 (Source: Clinical and Developmental Immunology)
Source: Clinical and Developmental Immunology - June 25, 2022 Category: Allergy & Immunology Authors: Mei Hu Zhitao Chen Yusheng Liao Jie Wu Dan Zheng Heng Zhang Source Type: research

Clinical value of the expression levels of protein tyrosine phosphatase non-receptor type 22.6 mRNA in peripheral blood mononuclear cells in Crohn's disease
CONCLUSIONS: The expression levels of PTPN22.6 mRNA can be used as an indicator to help predict CD diagnosis, disease activity, serum CRP level and behavior type of CD disease.PMID:35751647 | DOI:10.1093/cei/uxac061 (Source: Clinical and Developmental Immunology)
Source: Clinical and Developmental Immunology - June 25, 2022 Category: Allergy & Immunology Authors: Mei Hu Zhitao Chen Yusheng Liao Jie Wu Dan Zheng Heng Zhang Source Type: research

Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review
AbstractUstekinumab is approved for the treatment of psoriasis and Crohn ’s disease. Because many dermatological conditions are due to immune-mediated development, ustekinumab may be effective in other conditions. A systematic review of the off-label uses of ustekinumab, as well as on-label adverse effect, was performed, reporting on clinical improvement. MEDLINE, Emba se, Web of Science, and Cochrane databases were searched for studies regarding ustekinumab treatment of rativa (HS), lichen planus (LP), pyoderma gangrenosum (PG), pityriasis rubra pilaris (PRP), cutalopecia areata (AA), atopic dermatitis (AD), Bechet’s ...
Source: Archives of Dermatological Research - June 24, 2022 Category: Dermatology Source Type: research

Identification of healthspan-promoting genes in Caenorhabditis elegans based on a human GWAS study
Biogerontology. 2022 Jun 24. doi: 10.1007/s10522-022-09969-8. Online ahead of print.ABSTRACTTo find drivers of healthy ageing, a genome-wide association study (GWAS) was performed in healthy and unhealthy older individuals. Healthy individuals were defined as free from cardiovascular disease, stroke, heart failure, major adverse cardiovascular event, diabetes, dementia, cancer, chronic obstructive pulmonary disease (COPD), asthma, rheumatism, Crohn's disease, malabsorption or kidney disease. Six single nucleotide polymorphisms (SNPs) with unknown function associated with ten human genes were identified as candidate healths...
Source: Biogerontology - June 24, 2022 Category: Geriatrics Authors: Nadine Saul Ineke Dhondt Mikko Kuokkanen Markus Perola Clara Verschuuren Brecht Wouters Henrik von Chrzanowski Winnok H De Vos Liesbet Temmerman Walter Luyten Aleksandra Ze čić Tim Loier Christian Schmitz-Linneweber Bart P Braeckman Source Type: research